Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Clinical Drug Investigation|March 16, 2010
Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRIGiovan Battista Ruffo, Zelia Borsellino, Liana Cuccia, et al.
Journal of Health Psychology|October 22, 2021
Uncertain crisis time affects psychosocial dimensions in beta-thalassemia patients during Covid-19 pandemic: A cross-sectional studyChiara Cerami, Gaia Chiara Santi, Irene Sammartano, et al.
Experimental Hematology & Oncology|August 15, 2020
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE studyImmacolata Tartaglione, Raffaella Origa, Antonis Kattamis, et al.
European Heart Journal. Cardiovascular Imaging|September 24, 2014
Improvement of heart iron with preserved patterns of iron store by CMR-guided chelation therapyAntonella Meloni, Vincenzo Positano, Giovan Battista Ruffo, et al.
European Journal of Haematology|June 15, 2026
Pancreatic Iron Overload Is Associated With Early QTc Prolongation Before Myocardial Iron Deposition in Transfusion-Dependent ThalassemiaAntonella Meloni, Laura Pistoia, Giovan Battista Ruffo, et al.
Health and Quality of Life Outcomes|November 21, 2018
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemiasAli T Taher, Raffaella Origa, Silverio Perrotta, et al.
Journal of Clinical Medicine|December 9, 2023
Nephrological Complications in Hemoglobinopathies: SITE Good PracticeGiovan Battista Ruffo, Rodolfo Russo, Tommaso Casini, et al.
American Journal of Hematology|February 1, 2017
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE studyAli T Taher, Raffaella Origa, Silverio Perrotta, et al.
American Journal of Hematology|October 3, 2025
Quantifying Morbidity Risk Attributed to Red-Cell Transfusion Volume in Optimally Transfused Patients With β-ThalassemiaKhaled M Musallam, Angela Vitrano, Alessandro Inzerillo, et al.
British Journal of Haematology|August 1, 2025
Impact of lifetime anaemia and iron control on outcomes in β-thalassaemia: Data from the longitudinal de-LIGHT studyKhaled M Musallam, Angela Vitrano, Alessandro Inzerillo, et al.
Pageof 2